Themis Medicare Ltd Stock Price Today (NSE: THEMISMED)
Fundamental Score
Themis Medicare Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Themis Medicare Ltd share price today is ₹102.64, up +1.12% on NSE/BSE as of 17 June 2026. Themis Medicare Ltd (THEMISMED) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹969.87 (Cr). The 52-week high for THEMISMED share price is ₹148.00 and the 52-week low is ₹64.95. The company has a Return on Equity (ROE) of 7.65% and a debt-to-equity ratio of 0.25.
Themis Medicare Ltd Share Price Chart — NSE/BSE Historical Performance
Themis Medicare Ltd share price chart: 16.92% return over the past month. 52-week high ₹148.00, 52-week low ₹64.95.
Themis Medicare Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹105.01 | ₹110.48 | ₹104.58 | ₹108.12 | 1.17L (Cr) | |
| ₹110.00 | ₹110.89 | ₹103.75 | ₹105.35 | 76.70K (Cr) | |
| ₹113.91 | ₹117.50 | ₹108.15 | ₹109.56 | 1.43L (Cr) | |
| ₹107.80 | ₹115.89 | ₹107.80 | ₹113.90 | 4.37L (Cr) | |
| ₹103.45 | ₹108.11 | ₹99.01 | ₹106.46 | 2.42L (Cr) | |
| ₹101.99 | ₹101.99 | ₹99.42 | ₹100.24 | 29.18K (Cr) | |
| ₹99.13 | ₹105.26 | ₹98.00 | ₹100.29 | 90.27K (Cr) | |
| ₹98.90 | ₹99.99 | ₹97.85 | ₹98.64 | 30.81K (Cr) | |
| ₹97.46 | ₹101.00 | ₹96.25 | ₹97.46 | 47.33K (Cr) | |
| ₹96.76 | ₹101.65 | ₹96.76 | ₹98.14 | 58.55K (Cr) |
Themis Medicare Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹110.00 | ₹110.89 | ₹103.75 | ₹108.12 | -1.71% | |
| ₹98.60 | ₹117.50 | ₹94.43 | ₹109.56 | +11.12% | |
| ₹67.00 | ₹100.00 | ₹67.00 | ₹98.70 | +47.31% | |
| ₹82.01 | ₹84.89 | ₹64.95 | ₹66.07 | -19.44% | |
| ₹77.50 | ₹96.00 | ₹75.15 | ₹85.80 | +10.71% | |
| ₹101.91 | ₹108.29 | ₹76.00 | ₹80.18 | -21.32% | |
| ₹109.40 | ₹112.40 | ₹98.02 | ₹100.60 | -8.04% | |
| ₹124.80 | ₹125.80 | ₹101.15 | ₹107.86 | -13.57% | |
| ₹135.50 | ₹147.00 | ₹123.00 | ₹124.22 | -8.32% | |
| ₹97.60 | ₹148.00 | ₹97.60 | ₹134.81 | +38.12% | |
| ₹107.11 | ₹118.79 | ₹97.52 | ₹98.60 | -7.95% | |
| ₹130.95 | ₹131.89 | ₹106.68 | ₹107.49 | -17.92% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Themis Medicare Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Themis Medicare Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of THEMISMED across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Operating Margins (17.72%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Consistent Growth Track Record (15.00% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Conservative Debt Levels (D/E: 0.25)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Cash Generation (₹66.09 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (67.15%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
7 factors identified
Below-Average Return on Equity (7.65%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Profit Decline Concern (-125.33%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-33.35%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Weak Earnings Growth (3.88% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (3.91% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (-1.58x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 0.07%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Themis Medicare Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Themis Medicare Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Themis Medicare LtdThemis Medicare...Selected✓ THEMISMED • 530199 | 30/100 | ₹102.64₹103 | ₹969.87₹969.87 | — — | 7.65%Poor 7.65% Poor | 10.37%Average 10.37% Average | 0.25Excellent 0.3 Excellent | 3.91%Average 3.91% Average | 15.00%Excellent 15.00% Excellent | 0.48% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1796.50₹1797 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6553.50₹6554 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4350.40₹4350 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1390.30₹1390 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1290.40₹1290 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2262.90₹2263 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹1091.20₹1091 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2320.20₹2320 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1433.70₹1434 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5314.50₹5315 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Themis Medicare Ltd PE Ratio History
Historical price-to-earnings ratio for THEMISMED — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹3.24 | ₹100.60 | 31x |
| FY 2024 | ₹4.72 | ₹263.55 | 55.8x |
| FY 2023 | ₹6.17 | ₹213.70 | 34.6x |
| FY 2022 | ₹7.91 | ₹135.50 | 17.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Themis Medicare Ltd Dividend History
Annual cash dividends paid by THEMISMED — dividend yield 0.48%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹4.60 Cr |
| FY 2024 | ₹4.60 Cr |
| FY 2023 | ₹4.60 Cr |
| FY 2022 | ₹3.96 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Themis Medicare Ltd Quarterly Performance
Latest quarterly metrics for THEMISMED — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-33.35%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-125.33%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
15.00%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
3.91%
Compounded annual net profit growth over 5 years
Themis Medicare Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for THEMISMED — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Themis Medicare Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Themis Medicare Ltd (THEMISMED) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Themis Medicare Ltd
About THEMISMED (Themis Medicare Ltd)
Themis Medicare Ltd is a dynamic pharmaceutical company focused on developing, manufacturing, and marketing a diverse portfolio of pharmaceutical products. With a commitment to inn...ovation and quality, Themis Medicare caters to a broad spectrum of therapeutic needs, positioning itself as a significant player in both domestic and international markets. Their research and development efforts are geared towards creating effective and accessible medicines, with a strong emphasis on addressing prevalent health challenges. The company's strategic vision encompasses expanding its product line and strengthening its global footprint through strategic partnerships and collaborations, ensuring sustainable growth and value creation for its stakeholders. Themis Medicare distinguishes itself through a vertically integrated business model, encompassing the production of both active pharmaceutical ingredients (APIs) and finished formulations. This allows for greater control over the supply chain, ensuring consistent quality and cost-effectiveness. The company's product range includes medications targeting key therapeutic areas such as pain management, infectious diseases, diabetes, and cardiovascular health. By focusing on these critical areas, Themis Medicare aims to make a tangible difference in patient outcomes and contribute to improved public health. Its manufacturing facilities adhere to stringent international quality standards, further solidifying its reputation for reliability and excellence. Beyond its core business activities, Themis Medicare is deeply committed to ethical practices and corporate social responsibility. The company actively engages in initiatives aimed at improving access to healthcare and promoting health awareness within communities. By investing in research, technology, and human capital, Themis Medicare strives to remain at the forefront of the pharmaceutical industry, constantly adapting to evolving market demands and patient needs. This forward-thinking approach, coupled with a dedication to quality and innovation, positions Themis Medicare as a trusted provider of pharmaceutical solutions.
Company Details
Key Leadership
Corporate Events
THEMISMED Share Price: Frequently Asked Questions
What is the current share price of Themis Medicare Ltd?
Themis Medicare Ltd (THEMISMED) trades at ₹102.64 on NSE and BSE. Market cap ₹969.87 (Cr). Educational data only.
What is the P/E ratio of Themis Medicare Ltd?
Themis Medicare Ltd has a P/E of N/Ax vs industry average 31.77x.
What is the Bull Run score for Themis Medicare Ltd?
Themis Medicare Ltd has a Bull Run score of 30/100 based on 25+ financial parameters.
Does Themis Medicare Ltd pay dividends?
Themis Medicare Ltd has a dividend yield of 0.48%. Past dividends don't guarantee future payments.
What is the ROE of Themis Medicare Ltd?
Themis Medicare Ltd has ROE of 7.65%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Themis Medicare Ltd?
Themis Medicare Ltd has debt-to-equity of 0.25.
Is Themis Medicare Ltd a good investment?
Bull Run gives Themis Medicare Ltd a score of 30/100. This is not investment advice — consult a SEBI-registered advisor.